Toyama Chemical Begins Clinical Trials Of Flu Drug In U.S., Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Toyama Chemical's T-705, a pyrazine derivative antiviral influenza drug, could be ready for application in the U.S. and Japan by fall 2009, Toyama General Manager Shunjiro Misumi told PharmAsia News. Phase I trials are being conducted in the U.S., and Phase II trials are underway in Japan. Phase II results should be available in the spring, Misumi said. "In the Phase I studies conducted in the U.S. and Japan, we don't see any problems; no side effects have been observed," he said. The drug, which completely inhibits virus replication, has been shown to be effective on all types of influenza, including avian flu, company President Masuji Sugata told a Nov. 5 press conference in Tokyo